Loading...

APC anti-mouse CD86 Antibody

Pricing & Availability
Clone
GL-1 (See other available formats)
Regulatory Status
RUO
Other Names
B7-2, B70, Ly-58
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
GL-1_APC_090707
LPS-stimulated (3 days) C57BL/6 mouse splenocytes stained with GL-1 APC
  • GL-1_APC_090707
    LPS-stimulated (3 days) C57BL/6 mouse splenocytes stained with GL-1 APC
Compare all formats See APC spectral data
Cat # Size Price Save
105011 25 µg ¥16,520
105012 100 µg ¥55,180
Description

CD86 is an 80 kD immunoglobulin superfamily member also known as B7-2, B70, and Ly-58. CD86 is expressed on activated B and T cells, macrophages, dendritic cells, and astrocytes. CD86, along with CD80, is a ligand of CD28 and CD152 (CTLA-4). CD86 is expressed earlier in the immune response than CD80. CD86 has also been shown to be involved in immunoglobulin class-switching and triggering of NK cell-mediated cytotoxicity. CD86 binds to CD28 to transduce co-stimulatory signals for T cell activation, proliferation, and cytokine production. CD86 can also bind to CD152, also known as CTLA-4, to deliver an inhibitory signal to T cells.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
LPS-activated CBA/Ca mouse splenic B cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

The GL-1 antibody can block the mixed lymphocyte reaction in vitro and has been shown to inhibit the priming of cytotoxic T lymphocytes in vivo (along with antibodies against B7-1). Additional reported applications (for the relevant formats) include: immunoprecipitation1, immunohistochemical staining of acetone-fixed frozen sections2,6, immunofluorescence microscopy, and in vivo and in vitro blocking of T cell responses1-6. GL-1 is not suitable for immunohistochemical staining of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 105051-105056).

Application References

(PubMed link indicates BioLegend citation)
  1. Hathcock KS, et al. 1993. Science 262:905. (Block, IP)
  2. Inaba KM, et al. 1994. J. Exp. Med. 180:1849. (Block, IHC)
  3. Hathcock KS, et al. 1994. J. Exp. Med. 180:631. (Block)
  4. Krummel MF, et al. 1995. J. Exp. Med. 182:459. (Block)
  5. Liu Y, et al. 1997. J. Exp. Med. 185:251. (Block)
  6. Herold KC, et al. 1997. J. Immunol. 158:984. (Block, IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Lawson BR, et al. 2007. J. Immunol. 178:5366.
  9. Turnquist HR, et al. 2007. J. Immunol. 178:7018.
  10. Klinger MB, et al. 2007. Am. J. Physiol. Requl. Integr. Comp. Physiol. 293:R677. PubMed
  11. de Verteuil DA, et al. 2014. J Immunol. 193:1121. PubMed
Product Citations
  1. Arora H, et al. 2019. Immunity. 50:418. PubMed
  2. Yu X, et al. 2020. Nat Commun. 11:1110. PubMed
  3. Sohn HS, et al. 2022. Sci Adv. 8:eabo5284. PubMed
  4. Gao L, et al. 2023. J Nanobiotechnology. 21:56. PubMed
  5. Stoler-Barak L, et al. 2023. Nat Commun. 14:1462. PubMed
  6. Huang T, et al. 2023. Front Immunol. 14:1124152. PubMed
  7. Fu S, et al. 2023. Nat Commun. 14:2248. PubMed
  8. Zuo B, et al. 2023. Clin Transl Oncol. . PubMed
  9. Li T, et al. 2023. Nat Commun. 14:2498. PubMed
  10. Wu N, et al. 2023. Front Bioeng Biotechnol. 11:1173381. PubMed
  11. Zhang J, et al. 2023. Theranostics. 13:2226. PubMed
  12. Wang K, et al. 2023. Nat Commun. 14:2950. PubMed
  13. Wang HH, et al. 2022. J Biomed Sci. 29:36. PubMed
  14. D'Avola A, et al. 2022. J Clin Invest. 132: . PubMed
  15. Yue Y, et al. 2022. Nat Biomed Eng. 6:898. PubMed
  16. Li D, et al. 2022. Cell Prolif. 55:e13299. PubMed
  17. Blanco LP, et al. 2022. Arthritis Rheumatol. 74:1971. PubMed
  18. Li Y, et al. 2023. Bioact Mater. 20:548. PubMed
  19. Sun Y, et al. 2023. Bioact Mater. 22:47. PubMed
  20. Meng Z, et al. 2022. Int J Oncol. 61: . PubMed
  21. Xu S, et al. 2022. EBioMedicine. 86:104312. PubMed
  22. Liu M, et al. 2022. Cells. 11: . PubMed
  23. Li J, et al. 2022. Front Immunol. 13:1043484. PubMed
  24. Kraemer AN, et al. 2022. Front Immunol. 13:933191. PubMed
  25. Ivasko SM, et al. 2023. Front Immunol. 13:1023206. PubMed
  26. Zhao M, et al. 2023. J Nanobiotechnology. 21:50. PubMed
  27. Friedman D, et al. 2022. J Immunol. 208:1845. PubMed
  28. Bruggemann TR, et al. 2022. iScience. 25:105185. PubMed
  29. Zenke S, et al. 2022. Nat Commun. 13:6459. PubMed
  30. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  31. Wilhelm J, et al. 2021. J Control Release. 329:353. PubMed
  32. Verteuil D, et al. 2014. J Immunol. 193:1121. PubMed
  33. Kashyap AS, et al. 2019. Cell Rep. 28:3367. PubMed
  34. Yuzhu Hou et al. 2018. Immunity. 49(3):490-503 . PubMed
  35. Larsen SE, et al. 2021. Sci Rep. 11:9040. PubMed
  36. Oda SK, et al. 2020. J Exp Med. 217: . PubMed
  37. Tsuchiya N, et al. 2020. Cell Reports. 29(1):162-175.e9.. PubMed
  38. Go DM, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:715. PubMed
  39. Cho H, et al. 2022. Nat Commun. 13:5974. PubMed
  40. Mul Fedele ML, et al. 2020. Front Cell Infect Microbiol. 10:100. PubMed
  41. Xiao Y, et al. 2019. JCI Insight. 4:e99052. PubMed
  42. Bhattacharjee P, et al. 2018. Sci Rep. 13:e0199785. PubMed
  43. Hu M, et al. 2022. Can Respir J. 2022:5802938. PubMed
  44. Wu J, et al. 2021. Mol Med Rep. 23:. PubMed
  45. Sitnik S, et al. 2020. Mol Ther Oncolytics. 17:190. PubMed
  46. Park S, et al. 2021. Nat Cell Biol. 23:476. PubMed
  47. Shan M et al. 2018. Immunity. 49(4):709-724 . PubMed
  48. Cheng K, et al. 2021. Nat Commun. 12:2041. PubMed
  49. Zheng Y, et al. 2022. Front Pharmacol. 12:816032. PubMed
  50. Wu L, et al. 2022. Front Cell Dev Biol. 9:684842. PubMed
  51. Jing L, et al. 2022. Front Immunol. 13:864995. PubMed
  52. Zhang X, et al. 2021. Front Immunol. 12:680068. PubMed
  53. Sellau J, et al. 2016. Sci Rep. 6:28058. PubMed
  54. Yu X, et al. 2020. Cancer Cell. 37(6):850-866. PubMed
  55. Wang Y, et al. 2021. Cell Rep. 35:108948. PubMed
  56. Reed J, et al. 2020. Bio Protoc. 10:e3607. PubMed
  57. Gozgit JM, et al. 2021. Cancer Cell. :. PubMed
  58. Zhao X, et al. 2022. Nat Protoc. 17:2240. PubMed
  59. Roberts LM, et al. 2021. iScience. 24:103025. PubMed
  60. Chen G, et al. 2021. Sci Adv. 7:eabg5686. PubMed
  61. Liang J, et al. 2020. Sci Adv. 6:eabc3646. PubMed
  62. Qian J, et al. 2021. Int J Mol Sci. 22:. PubMed
  63. Coronel MM, et al. 2020. Sci Adv. 6:eaba5573. PubMed
  64. Yamada KJ, et al. 2020. PLoS Pathog. 16:e1008354. PubMed
  65. Yang C, et al. 2019. Nanomedicine (Lond). 14:2423. PubMed
  66. Yu X, et al. 2019. Nat Commun. 10:574. PubMed
  67. Landon J Edgar et al. 2018. Cell chemical biology. 26(1):131-136 . PubMed
  68. Zhang X, et al. 2022. JCI Insight. 7:. PubMed
  69. Kang X, et al. 2022. J Immunol Res. 2022:8118577. PubMed
  70. Anderson AE, et al. 2022. NPJ Regen Med. 7:6. PubMed
  71. Sun S, et al. 2021. Front Immunol. 12:777665. PubMed
  72. Han F, et al. 2020. Invest Ophthalmol Vis Sci. 61:24. PubMed
  73. Seki T, et al. 2015. J Biochem. 158: 485 - 495. PubMed
  74. Shepherd J 2011. Toxicol Sci. 120:68. PubMed
  75. Xu Q, et al. 2021. Theranostics. 11:1937. PubMed
  76. Qiu N, et al. 2021. J Nanobiotechnology. 19:428. PubMed
  77. Gómez LA, et al. 2020. Front Microbiol. 11:1586. PubMed
  78. Lu SW, et al. 2020. Nat Commun. 3.660416667. PubMed
  79. He J, et al. 2020. Evid Based Complement Alternat Med. 2020:5637507. PubMed
  80. Luck H, et al. 2019. Nat Commun. 10:3650. PubMed
  81. Zhao F et al. 2018. Immunity. 48(1):147-160 . PubMed
  82. Li Z, et al. 2022. Nat Commun. 13:6321. PubMed
  83. Qi J, et al. 2021. Nat Commun. 12:4755. PubMed
  84. Bent EH, et al. 2021. Nat Commun. 12:6218. PubMed
  85. Li ZL, et al. 2021. Mol Ther Nucleic Acids. 25:502. PubMed
  86. Bi CS, et al. 2020. Cell Prolif. 53:e12827. PubMed
  87. Gong N, et al. 2020. Nat Nanotechnol. 1.35625. PubMed
  88. Zheng B, et al. 2021. Bioact Mater. 6:3879. PubMed
  89. Wang L, et al. 2021. Sci Adv. 7:eabj4796. PubMed
  90. Huang L, et al. 2021. Frontiers in Cellular and Infection Microbiology. 10:606340. PubMed
  91. Zhang W, et al. 2021. Front Immunol. 12:768435. PubMed
  92. Yang Z, et al. 2021. Nat Commun. 12:4299. PubMed
  93. Singhal P, et al. 2016. Proc Natl Acad Sci U S A. 113: 122 - 127. PubMed
  94. Dai X, et al. 2021. Molecular Cell. 81(11):2317-2331.e6. PubMed
  95. Zheng C, et al. 2022. Acta Pharm Sin B. 12:3726. PubMed
  96. Bahmani B, et al. 2021. Nat Commun. 12:1999. PubMed
  97. Ukidve A, et al. 2020. Proc Natl Acad Sci U S A. 117:17727. PubMed
  98. Radulovic V, et al. 2020. Cell Reports. 27(10):2826-2836.e5.. PubMed
  99. Chen R, et al. 2021. Front Oncol. 11:743050. PubMed
  100. Zhang M, et al. 2022. iScience. 25:104490. PubMed
  101. Qi S, et al. 2020. Theranostics. 10:1814. PubMed
  102. Finkin S et al. 2019. Immunity. 51(2):324-336 . PubMed
  103. Liu WL, et al. 2019. Nat Commun. 10:3199. PubMed
  104. Trivedi S, et al. 2020. Elife. 9:00. PubMed
RRID
AB_493343 (BioLegend Cat. No. 105011)
AB_493343 (BioLegend Cat. No. 105012)

Antigen Details

Structure
Ig superfamily, 80 kD
Distribution

B cells and T cells (upregulated upon activation), macrophages, dendritic cells, and astrocytes

Function
T cell costimulation, Ig class-switching, NK cell cytotoxicity
Ligand/Receptor
CD28, CD152 (CTLA-4)
Cell Type
Astrocytes, B cells, Dendritic cells, Macrophages, T cells, Tregs
Biology Area
Cell Biology, Costimulatory Molecules, Immunology, Neuroscience, Neuroscience Cell Markers
Molecular Family
CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Hathcock KS, et al. 1993. Science 262:905.
3. Freeman GJ, et al. 1993. Science 262:907.
4. Carreno BM, et al. 2002. Annu. Rev. Immunol. 20:29.

Gene ID
12524 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD86
Specificity Alt (DOES NOT SHOW ON TDS):
CD86
App Abbreviation (DOES NOT SHOW ON TDS):
FC
UniProt
View information about CD86 on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account